The novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody (RG7802, RO6958688) showed antitumor activity in patients with advanced colorectal cancer, which was enhanced in combination with atezolizumab (24). Here, CEACAM5 is linked to colorectal cancer.